Tuoxin Pharmaceutical Group Co.,Ltd. (SHE:301089)
China · Delayed Price · Currency is CNY 20.55
-0.47 (-2.24%)
At close: Nov 13, 2026
SHE:301089 Balance Sheet
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Equivalents | 81.65 | 140.26 | 69.23 | 148.55 | 307.09 | 284.22 |
Trading Asset Securities | 110.22 | 105.15 | 250.88 | 190.7 | 240.16 | 220.62 |
Cash & Short-Term Investments | 191.87 | 245.41 | 320.11 | 339.26 | 547.25 | 504.84 |
Cash Growth | -24.71% | -23.34% | -5.64% | -38.01% | 8.40% | 219.08% |
Accounts Receivable | 108.77 | 126.13 | 151.52 | 235.3 | 205.41 | 103.58 |
Other Receivables | 1.06 | 23.8 | 21.32 | 12.57 | 13.66 | 0.62 |
Receivables | 109.83 | 149.93 | 172.84 | 247.87 | 219.07 | 104.2 |
Inventory | 205.31 | 181.61 | 178.88 | 204.11 | 241.14 | 167.08 |
Other Current Assets | 37.43 | 8 | 5.18 | 30.93 | 6.54 | 20.64 |
Total Current Assets | 544.44 | 584.95 | 677.01 | 822.17 | 1,014 | 796.76 |
Property, Plant & Equipment | 830.01 | 862.77 | 874.54 | 809.38 | 610.26 | 449.11 |
Long-Term Investments | 19.7 | 19.7 | 7.95 | 8.37 | 10.86 | 12.54 |
Other Intangible Assets | 99.54 | 80.12 | 81.83 | 84.04 | 84.26 | 84.56 |
Long-Term Accounts Receivable | - | 0.27 | 0.26 | - | - | - |
Long-Term Deferred Tax Assets | 73.38 | 70.98 | 69.58 | 63.71 | 70.36 | 6.51 |
Long-Term Deferred Charges | 2.89 | 3.62 | 4 | 2.7 | 1.86 | 2.33 |
Other Long-Term Assets | 45.49 | 42.89 | 43.08 | 48.62 | 51.64 | 41.9 |
Total Assets | 1,615 | 1,665 | 1,758 | 1,839 | 1,843 | 1,394 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Accounts Payable | 103.08 | 118.01 | 133.21 | 152.55 | 158.58 | 162.94 |
Accrued Expenses | 8.95 | 17.31 | 22.81 | 24.58 | 69.09 | 17.51 |
Short-Term Debt | - | - | - | - | 40.03 | 64.5 |
Current Portion of Long-Term Debt | 1.07 | - | - | - | - | - |
Current Portion of Leases | - | 1.01 | 0.97 | - | - | 4.91 |
Current Income Taxes Payable | 4.02 | 0 | - | 0 | 66.05 | 1.31 |
Current Unearned Revenue | 7.68 | 1.69 | 0.91 | 5.48 | 71.89 | 2.9 |
Other Current Liabilities | 13.86 | 7.94 | 7.43 | 11.9 | 18.32 | 0.53 |
Total Current Liabilities | 138.66 | 145.97 | 165.32 | 194.51 | 423.96 | 254.6 |
Long-Term Leases | 1.15 | 2.24 | 3.25 | - | - | - |
Long-Term Unearned Revenue | 28.37 | 30.55 | 32.94 | 35.17 | 38.31 | 40.4 |
Long-Term Deferred Tax Liabilities | 2.22 | 2.36 | 4.21 | 6.04 | 4.61 | 1.36 |
Total Liabilities | 170.41 | 181.12 | 205.72 | 235.72 | 466.89 | 296.35 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Common Stock | 126.54 | 126.54 | 126.54 | 126.54 | 126 | 126 |
Additional Paid-In Capital | 621.11 | 621.11 | 621.11 | 621.11 | 585.3 | 578.54 |
Retained Earnings | 692.04 | 732.99 | 802.66 | 854.18 | 661.5 | 387.57 |
Comprehensive Income & Other | 5.35 | 3.53 | 2.21 | 1.44 | 3.57 | 5.25 |
Total Common Equity | 1,445 | 1,484 | 1,553 | 1,603 | 1,376 | 1,097 |
Shareholders' Equity | 1,445 | 1,484 | 1,553 | 1,603 | 1,376 | 1,097 |
Total Liabilities & Equity | 1,615 | 1,665 | 1,758 | 1,839 | 1,843 | 1,394 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Total Debt | 2.22 | 3.25 | 4.22 | - | 40.03 | 69.41 |
Net Cash (Debt) | 189.65 | 242.16 | 315.89 | 339.26 | 507.22 | 435.43 |
Net Cash Growth | -24.63% | -23.34% | -6.89% | -33.11% | 16.49% | - |
Net Cash Per Share | 1.48 | 1.91 | 2.54 | 2.69 | 4.02 | 4.37 |
Filing Date Shares Outstanding | 129.77 | 126.54 | 126.54 | 126.54 | 126 | 126 |
Total Common Shares Outstanding | 129.77 | 126.54 | 126.54 | 126.54 | 126 | 126 |
Working Capital | 405.77 | 438.98 | 511.69 | 627.66 | 590.04 | 542.16 |
Book Value Per Share | 11.14 | 11.73 | 12.27 | 12.67 | 10.92 | 8.71 |
Tangible Book Value | 1,346 | 1,404 | 1,471 | 1,519 | 1,292 | 1,013 |
Tangible Book Value Per Share | 10.37 | 11.10 | 11.62 | 12.01 | 10.25 | 8.04 |
Buildings | - | 424.24 | 283.94 | 267.66 | 257.26 | 210.62 |
Machinery | - | 657.07 | 420.02 | 382.3 | 354.84 | 301.65 |
Construction In Progress | - | 44.71 | 372.68 | 331.03 | 130.48 | 35.59 |